Item 2.02. Results of Operations and Financial Condition.
On
The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished pursuant to Item 2.02 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing to this item of this report.
Item 7.01. Regulation FD Disclosure.
On
The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2, is being furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this item of this report.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Exhibit No. Description Press Release, datedMay 16, 2022 , entitled "PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business 99.1 Highlights". 99.2 Corporate Presentation, datedMay 16, 2022 . 104 Cover page interactive data file (formatted as Inline XBRL).
--------------------------------------------------------------------------------
© Edgar Online, source